Insulet Co. (NASDAQ:PODD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $318.41.

PODD has been the topic of a number of analyst reports. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 target price on the stock in a research note on Tuesday, May 13th. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a research note on Friday, May 30th. Raymond James restated an “outperform” rating and set a $360.00 target price (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Wells Fargo & Company set a $322.00 price target on Insulet in a research report on Monday, April 28th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Insulet in a research note on Friday, May 16th.

Insiders Place Their Bets

In related news, SVP John W. Kapples sold 5,278 shares of the business’s stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president now directly owns 23,180 shares of the company’s stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares in the company, valued at $888,525. This represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

A number of institutional investors have recently bought and sold shares of PODD. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter valued at $36,000. Vontobel Holding Ltd. grew its stake in Insulet by 4.3% in the fourth quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier’s stock valued at $633,000 after acquiring an additional 100 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Insulet in the fourth quarter worth about $9,822,000. Summit Trail Advisors LLC acquired a new stake in shares of Insulet during the fourth quarter worth about $491,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier’s stock valued at $274,000 after purchasing an additional 50 shares in the last quarter.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $302.24 on Thursday. The firm has a market capitalization of $21.27 billion, a PE ratio of 52.20, a PEG ratio of 3.62 and a beta of 1.37. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet has a 1-year low of $173.00 and a 1-year high of $329.33. The business’s 50 day moving average is $285.05 and its 200-day moving average is $274.43.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Insulet’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same period last year, the business earned $0.73 earnings per share. Sell-side analysts predict that Insulet will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.